Roche’s Pipeline Prospects Promise Steady Sailing To More Growth
Analysts increasingly see Roche’s pipeline and newly launched drugs winning over investors and neutralizing worries over biosimilars and potential US pricing reforms. Its 16 September pipeline update in London may reinforce that.
You may also be interested in...
Roche Ups Outlook, Sees Spark Buy By Year-End
Roche presented another strong quarterly performance and raised its outlook again for the full year, as sales continued to be driven in the third quarter by its portfolio of new medicines. It still believes its delayed takeover of Spark Therapeutics will happen by year-end.
Deal Watch: BMS To Tap Early-Stage Breakthroughs In Partnership With BioMotiv
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.
Roche's New Chief Medical Officer Levi Garraway Brings Deep Cancer Genomics Expertise
CMO Sandra Horning will retire at the end of the year, to be succeeded by Lilly's former senior VP of oncology R&D on 1 October.